Stock Price
P/E Ratio
Volume Traded Today
Dividend
52 Week High/low
Merit Medical Systems Inc Market Cap
The Merit Medical Systems Inc (MMSI) share price is expected to increase by 5.45% over the next year. This is based on calculating the average 12-month share price estimate provided by 11 stock analysts who have covered MMSI. Price targets range from $103 at the low end to $125 at the high end. The current analyst consensus for MMSI is a buy. Please note analyst price targets are not guaranteed and could be missed completely.
Merit Medical Systems Inc has a total of 11 Wall St Analyst ratings. There are 9 buy ratings, 2 ratings, and 0 sell ratings. Since most analysts have a buy consensus rating, the expectation is that Merit Medical Systems Inc will outperform the market. Investors shouldn't rely purely on analyst ratings; we encourage investors to also take a look at the fundamental and technical analysis in their due diligence.
These are the latest 20 analyst ratings of MMSI.
|
Analyst/Firm |
Rating |
Price Target |
Change |
Date |
|---|---|---|---|---|
| Michael Petusky Barrington Research | Outperform | $114 | Maintains | Oct 31, 2024 |
| Mike Matson Needham | Buy | $109 | Reiterates | Oct 31, 2024 |
| David Rescott Baird | Outperform | $109 | Maintains | Oct 31, 2024 |
| Michael Petusky Barrington Research | Outperform | $114 | Maintains | Oct 18, 2024 |
| Michael Petusky Barrington Research | Outperform | $114 | Maintains | Sep 20, 2024 |
| Mike Matson Needham | Buy | $109 | Maintains | Sep 17, 2024 |
| Craig Bijou B of A Securities | Neutral | $103 | Maintains | Sep 16, 2024 |
| Mike Matson Needham | Buy | $105 | Reiterates | Sep 16, 2024 |
| Larry Biegelsen Wells Fargo | Equal-Weight | $103 | Maintains | Sep 16, 2024 |
| Jason Bednar Piper Sandler | Overweight | $110 | Reiterates | Sep 9, 2024 |
| Mike Matson Needham | Buy | $105 | Maintains | Aug 28, 2024 |
| Craig Bijou B of A Securities | Neutral | $92 | Maintains | Aug 5, 2024 |
| Mike Matson Needham | Buy | $94 | Maintains | Aug 2, 2024 |
| Jason Bednar Piper Sandler | Overweight | $100 | Maintains | Aug 2, 2024 |
| Michael Petusky Barrington Research | Outperform | $100 | Maintains | Jul 16, 2024 |
| Jon Young Canaccord Genuity | Buy | $125 | Maintains | Jul 2, 2024 |
| Michael Petusky Barrington Research | Outperform | $100 | Maintains | Jul 2, 2024 |
| Mike Matson Needham | Buy | $93 | Maintains | Jul 1, 2024 |
| David Rescott Baird | Outperform | $96 | Initiates | Jun 28, 2024 |
| Mike Matson Needham | Buy | $85 | Maintains | May 1, 2024 |
When did it IPO
1992
Staff Count
6,950
Country
United States
Sector/Industry
Healthcare/Medical Instruments & Supplies
CEO
Mr. Fred P. Lampropoulos
Market Cap
$6.08B
In 2023, MMSI generated $1.26B in revenue, which was a increase of 9.24% from the previous year. This can be seen as a signal that MMSI's business is growing, and its share price could be worth more in the future. However, if the company grows faster (or slower) than expected, this could also have a major impact on the future share price.
Revenue From 2020
Revenue From 2021
Revenue From 2022
Revenue From 2023
Fri, 29 Nov 2024
Sentiment - NEUTRAL
Source - Zacks Investment Research
Summary - Investors should consider Merit Medical (MMSI) and West Pharmaceutical Services (WST) in the Medical - Dental Supplies sector for potential value opportunities.
Why It Matters - The comparison between Merit Medical and West Pharmaceutical Services highlights potential investment opportunities in the Medical - Dental Supplies sector, influencing stock selection and portfolio strategies.
Tue, 26 Nov 2024
Sentiment - NEUTRAL
Source - Zacks Investment Research
Summary - Merit Medical's WRAPSODY device has improved patency rates for AVG patients, likely increasing vascular access survival for these individuals.
Why It Matters - Improved patency rates from the WRAPSODY device may lead to increased demand and revenue for Merit Medical, positively impacting its stock performance and investor sentiment.
Mon, 25 Nov 2024
Sentiment - NEUTRAL
Source - GlobeNewsWire
Summary - WRAPSODY reports 82% target lesion primary patency at six months from its US pivotal trial's single-arm cohort, indicating strong outcomes for its treatment.
Why It Matters - The 82% primary patency rate for WRAPSODY indicates strong efficacy, potentially boosting investor confidence in the company's future growth and market competitiveness in the medical device sector.
Mon, 25 Nov 2024
Sentiment - NEUTRAL
Source - GlobeNewsWire
Summary - The global Fundus Camera market, valued at $459.4 million in 2024, is projected to reach $665.85 million by 2033, growing at a 4.21% CAGR due to rising demand for eye diagnostics.
Why It Matters - The fundus camera market's projected growth indicates rising demand for advanced eye diagnostics, signaling investment opportunities in medical technology and ophthalmic equipment sectors.
Wed, 20 Nov 2024
Sentiment - POSITIVE
Source - Zacks Investment Research
Summary - MMSI demonstrates strong growth with a solid product portfolio and recent acquisitions, enhancing its position in the competitive healthcare sector.
Why It Matters - MMSI's strong growth and strategic acquisitions enhance its market position, potentially leading to increased revenue and investor confidence in the healthcare sector.
Thu, 21 Nov 2024
Sentiment - POSITIVE
Source - Zacks Investment Research
Summary - Merit Medical (MMSI) is positioned for strong returns due to its solid growth attributes, indicating potential investment opportunities.
Why It Matters - Merit Medical's strong growth potential suggests increasing profitability, making it an attractive option for investors seeking high returns.
The information that Ticker Nerd provides is general in nature as it has been prepared without taking account of your objectives, financial situation or needs. It is not intended as legal, financial or investment advice and should not be construed or relied on as such. Ticker Nerd is for information purposes only. Ticker Nerd is not responsible for any damages or losses that may occur as a result of reliance on this information. Before making any commitment of a legal or financial nature you should seek advice from a qualified and registered legal practitioner or financial or investment adviser. All content, group, messaging, tweets, newsletter, article, and email created by Ticker Nerd is intended for educational and information purposes only, is not financial, investment, legal or tax advice, and is a restatement, summary or extract of other data and research reports that are widely distributed from sources such as, but not limited to, Bloomberg, Market Watch, Wall Street Journal, Google Finance, and Yahoo Finance. Ticker Nerd is not a registered financial, investment, legal or tax advisor and is not liable for any financial loss you may incur acting on any information provided by Ticker Nerd. By registering, you agree not to hold Ticker Nerd liable at any time or under any circumstances for your decisions, actions, or results.
